SEOM guideline in ovarian cancer 2014.

Ovarian cancer is the leading cause of death due to gynecological cancer and the 5th cause of death for cancer in women in Europe. Optimal management of patients with ovarian cancer needs the participation of a well-trained multidisciplinary team. In the last few years, we have observed a significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer that will probably change our standard of care in the forthcoming years. In this Guideline, we summarize the most current evidence for the medical management of ovarian cancer.

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first "Treatment Guidelines in Ovarian Cancer" were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308-316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750-755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript.

Update in the management of ovarian and cervical carcinoma.

Ovarian and cervical cancers are significant health problems. This article provides an update in selected management topics. Paclitaxel and platinum derivatives are the first-line treatment for patients with advanced disease. In selected patients, intraperitoneal chemotherapy has been associated with improved survival but the broad applicability of this strategy is limited by issues of toxicity and feasibility. Management of patients with recurrent disease is based on a number of factors and includes surgery in selected cases, platinum-based chemotherapy for patients with platinum-sensitive disease and other agents such as topotecan and pegylated liposomal formulation of doxorubicin for patients with platinum-resistant disease. In cervical cancer, the most significant issue/event is the demonstration of superior survival with topotecan and cisplatin compared to cisplatin alone. Finally, new agents such as epidermal growth factor receptor inhibitors and antiangiogenic agents are being currently tested in these settings.

Fluorescent characteristics of carbamazepine.

Previously undescribed carbamazepine fluorescence data were found in ethanolic solutions within a range of 200-550 nm. Concentrated H2S04, bidistilled ethanol and a 1:1 mixture of them showed lambda Exc. at 470 nm. A 10-fold fluorescence increase at 470 nm and 520 nm peaks were observed when 10 micrograms of ethanolic carbamazepine solution was activated with the same acid (1:1). A lambda Exc. of 300 nm and Anal. of 357 nm amounted to 60 per cent of the carbamazepine relative fluorescence values in comparison to 95 per cent when a 470/515 nm monochromators combination were used. A 12 hours fluorescence duration was detected for "activated" carbamazepine. The "filter effect" appeared within the range of 10 and 100 micrograms/ml of carbamazepine. Temperature induced an acute fluorescence decay starting at 23 degrees C. Identical wavelengths and others still unidentified were detected from carbamazepine extracted from human serum. The monochromators combination at 300/357 nm might be useful for serum extracted carbamazepine measurements.

Caracteristicas fluorescentes de la carbamacepina. / Fluorescent characteristics of carbamazepine

Describimos las caracteristicas fluorescentes de la carbamacepina. Esta, en solucion etanoliga, manifiesta lambda exc. a 470 y 520 nm.El etanol no muestra maximos de excitacion entre 200 y 550 nm; en cambio, el H2SO4 concentrado y su mezcla etanolica lo hacen a 479 nm, en proporcion 10 veces menor en ausencia de carbamacepina. Una meseta a lambda exc.de 300 nm y una lambda de anal de 357 brindan valores de 60 por ciento, en comparacion con 95 por ciento de fluorescencia relativa encontrados con la combinacion 470/515 nm para 10 micrograma de carbamacepina. Se detecta una duracion de 12 horas de la fluorescencia correspondiente a la carbamacepina "activada" El efecto de filtro se manifiesta entre los 10 y los 100 micrograma. La temperatura induce la declinacion de la emision despues de los 23oC hasta llegar a valores del reactivo de activacion a los 25oC. La carbamacepina extraida de suero humano revela las mismas lambdas exc. y valores intermedios correspondientes a compuestos sericos no investigados